Auxilium Pharmaceuticals, Inc. (AUXL) Posts Q1 Loss of 39c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Aegis Capital Sees Post-Q1 Pullback in Auxilium Pharma (AUXL) as Possible Entry Point
May 5, 2014 11:31 AM EDTAegis Capital affirms its Buy rating and $37 price target on Auxilium Pharmaceuticals (Nasdaq: AUXL) following Q1 results.
Analyst Ram Selvaraju commented, In our view, Auxilium's first quarter results were clearly a substantial disappointment, but we believe that the issues were restricted primarily to a significant miss on Testim revenues. Previously, Auxilium had expected $39mm in Testim sales based on IMS Health prescription data; the actual number was only $11mm. The firm's top-line revenues in 1Q 2014 came in at $88.5mm, well behind our... More
